Clinical Trials

Phase 1 Not yet recruiting

KRAS p.G12C Mutant Advanced Solid Tumors

NCT07426757 2026-03-12

An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

120 enrolled

Advanced Malignancies

NCT04973163 2026-02-17

A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

Phase 1 Active not recruiting

30 enrolled

Solid Tumors, KRAS Mutation

NCT07235748 2026-02-17

Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants

28 enrolled

Healthy Adult Participants

NCT06575933 2026-02-11

MK-1084-009

28 enrolled

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05646862 2026-02-05

INAVO121

420 enrolled

CNSDermatologicHead & NeckThoracic

Breast Neoplasms

NCT05355701 2026-02-03

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Phase 1 Recruiting

267 enrolled

Carcinoma, Non-Small-Cell Lung, Glioma, Melanoma, Thyroid Neoplasms

NCT02365597 2026-01-30

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Phase 2 Active not recruiting

239 enrolled 32 charts 1 FDA

Genitourinary

Urothelial Cancer

NCT07340190 2026-01-14

A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies

Phase 1 Not yet recruiting

24 enrolled

Advanced Malignancies

NCT04067336 2025-11-10

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2 Recruiting

263 enrolled 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04543188 2025-10-23

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

Phase 1 Terminated

65 enrolled 52 charts

CNSDermatologicThoracic

Brain Diseases, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Central Nervous System Neoplasms

NCT04557449 2025-10-01

CDK4i

Phase 2 Active not recruiting

362 enrolled

BreastGastrointestinalGenitourinarySarcomaThoracic

Adenocarcinoma of Lung, Breast Neoplasms, Liposarcoma, Prostatic Neoplasms, Colorectal Neoplasms

NCT06547164 2025-09-04

A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants

40 enrolled

Breast Neoplasms

NCT04051827 2025-07-28

Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

26 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01585623 2025-03-05

Drug Interaction Study of SAR302503 in Patients With Solid Tumor

16 enrolled

Solid Tumor

NCT04908176 2024-12-13

A Drug-drug Interaction Study of Avapritinib and Midazolam

CNSGastrointestinalSarcoma

10 enrolled

Glioblastoma, Neoplasms, Recurrence, Gastrointestinal Stromal Tumors

NCT05926180 2024-12-13

Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)

25 enrolled

Other hematologic neoplasm

Carcinoma, Non-Small-Cell Lung

NCT02014558 2024-12-03

Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2 Completed

265 enrolled 80 charts

Leukemia, Myeloid, Acute

NCT02113813 2024-11-14

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

133 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01296555 2024-07-31

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

Phase 1 Terminated

674 enrolled 55 charts

Lymphoid

Lymphoma, Non-Hodgkin

NCT06360211 2024-07-03

A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants

15 enrolled

Advanced Non-small Cell Lung Cancer

NCT04887194 2024-05-08

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

40 enrolled

Advanced Solid Tumor

NCT04958226 2024-01-25

A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours

21 enrolled

Solid Tumour

NCT05395117 2023-12-13

A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin

32 enrolled

Healthy Participants

NCT04718740 2023-08-14

A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer

33 enrolled

Gynecologic

Ovarian Neoplasms

NCT03420742 2023-01-27

A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors

24 enrolled 17 charts

Carcinoma, Lung Neoplasms, Neoplasms

NCT02857270 2022-11-22

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

DermatologicGastrointestinalThoracic

210 enrolled

Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT02688088 2022-10-18

A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body

48 enrolled 30 charts

Neoplasm Metastasis

NCT04727138 2022-05-16

3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546

64 enrolled

Neoplasms

NCT01655225 2022-04-08

A Study of LY3023414 in Participants With Advanced Cancer

BreastLymphoidOther solid neoplasmThoracic

156 enrolled

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Lymphoma, Non-Hodgkin, Mesothelioma, Neoplasm Metastasis

NCT05028608 2022-02-25

A Study to Learn What Happens to Elinzanetant in the Body When Taken With or Without Carbamazepine, and How Safe it is in Healthy Men and Women Aged 18 to 60 Years.

16 enrolled

Endocrine

Multiple Endocrine Neoplasia Type 1

NCT03291288 2021-05-14

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

32 enrolled 22 charts

Synovitis, Pigmented Villonodular

NCT02244112 2021-02-21

A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies

Phase 1 Terminated

43 enrolled

Neoplasms

NCT01456689 2020-12-17

A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

79 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02520752 2020-12-10

A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors

37 enrolled

cMET-dysregulated Advanced Solid Tumors

NCT03955939 2020-06-01

A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body

5 enrolled

Breast Neoplasms, Epilepsy

NCT01393990 2020-03-24

A Study of LY2228820 in Participants With Advanced Cancer

Other hematologic neoplasm

89 enrolled 30 charts

Advanced Cancer

NCT03760445 2020-01-09

HDM201 Added to CT in R/R or Newly Diagnosed AML

Phase 1/2 Withdrawn

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT03301207 2019-12-05

A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy

LymphoidOther hematologic neoplasm

25 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02686164 2019-08-28

Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors

51 enrolled 11 charts

Neoplasms

NCT01287598 2019-07-10

BAY73-4506 Probe Substrate Study

41 enrolled

Neoplasms

NCT01517399 2019-02-12

Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

28 enrolled

Neoplasms

NCT03237416 2018-11-06

Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers

15 enrolled

Genitourinary

Prostatic Neoplasms

NCT03330990 2018-08-21

Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients

15 enrolled

Advanced Solid Tumor

NCT00258050 2017-12-06

To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients

24 enrolled

Breast Neoplasms

NCT00880321 2017-11-13

A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors

170 enrolled

Neoplasms

NCT02082665 2017-07-24

Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam

6 enrolled

Dermatologic

Melanoma, Neoplasms

NCT01911728 2017-06-26

Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates

14 enrolled

Genitourinary

Pharmacokinetics of MDV3100

NCT00467779 2016-08-26

Study of Cobimetinib in Participants With Solid Tumors

119 enrolled 63 charts

Solid Tumor

NCT01071304 2015-04-10

Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)